<DOC>
	<DOCNO>NCT00214266</DOCNO>
	<brief_summary>The hypothesis study lymphocyte depletion Campath-1H rituximab obviate need long-term calcineurin inhibitor renal transplantation . Most successful strategy date rely use either tacrolimus cyclosporine . However , advantage calcineurin inhibitor free regimen may include improved renal allograft function , low incidence hypertension , diabetes , less drug relate side effect . This non-randomized open-label pilot trial 30 adult renal transplant patient .</brief_summary>
	<brief_title>A Pilot Study Campath-1H Induction Therapy Combined With CellCeptÂ® Therapy Allow Calcineurin Inhibitor Free Regimen After Renal Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Calcineurin Inhibitors</mesh_term>
	<criteria>renal transplant recipient Recipients HLAidentical livingdonor renal transplant ; multiorgan transplant ; know hypersensitivity Campath1H , Rituximab , CellCept , prednisone ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>